LEO pharma

LEO pharma

Develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients.

  • Edit
DateInvestorsAmountRound
*

€450m

Growth Equity non VC
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR201720182019202120222023
Revenues000000000000000000000000
% growth----702 %(86 %)
EBITDA000000000000000000000000
Profit000000000000000000000000
% profit margin---(49 %)(39 %)(32 %)
EV000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget000000000000000000000000

Source: Company filings or news article

Notes (0)
More about LEO pharma
Made with AI
Edit

LEO Pharma is a global pharmaceutical company specializing in dermatology, focusing on innovative treatments for skin diseases. The company operates in the healthcare market, primarily serving patients, healthcare professionals, and industry partners. LEO Pharma's business model revolves around research and development, leveraging its Open Innovation platform to collaborate with external partners. This platform allows partners to test proprietary compounds in advanced biological assays at no cost, without business obligations, and with full ownership of the data. The company generates revenue through the development and commercialization of dermatological drugs, as well as through strategic partnerships and collaborations. LEO Pharma's commitment to innovation and collaboration positions it as a leader in the dermatology sector.

Keywords: dermatology, bioassays, open innovation, skin diseases, pharmaceutical, partnerships, R&D, healthcare, drug development, collaboration.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by LEO pharma

Edit
BioPharmX
ACQUISITION by LEO pharma Aug 2023
Peplin
ACQUISITION by LEO pharma Sep 2009